نتائج البحث - "Caroline Robert"

1

The efficacy of immunotherapy for in-transit metastases of melanoma: an analysis of randomized controlled trials

المؤلفون: James Larkin, Jeffrey S. Weber, F. Stephen Hodi, Paolo A. Ascierto, Roger Olofsson Bagge, Georgina V. Long, Alexander C.J. van Akkooi, Jacob Schachter, Caroline Robert, Lars Ny

المصدر: Melanoma Research. 31:181-185

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3a480cb93e62763c98a1eb0a61f5b12Test
https://doi.org/10.1097/cmr.0000000000000719Test

2

Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma

المساهمون: HUS Comprehensive Cancer Center, Clinicum, Department of Oncology

المصدر: Eggermont, A MM, Meshcheryakov, A, Atkinson, V, Blank, C U, Mandala, M, Long, G V, Barrow, C, Di Giacomo, A M, Fisher, R, Sandhu, S, Kudchadkar, R, Ortiz Romero, P L, Svane, I M, Larkin, J, Puig, S, Hersey, P, Quaglino, P, Queirolo, P, Stroyakovskiy, D, Bastholt, L, Mohr, P, Hernberg, M, Chiarion-Sileni, V, Strother, M, Hauschild, A, Yamazaki, N, van Akkooi, A CJ, Lorigan, P, Krepler, C, Ibrahim, N, Marreaud, S, Kicinski, M, Suciu, S & Robert, C 2021, ' Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma ', European Journal of Cancer, vol. 158, pp. 156-168 . https://doi.org/10.1016/j.ejca.2021.09.023Test
Eggermont, A M, Meshcheryakov, A, Atkinson, V, Blank, C U, Mandala, M, Long, G V, Barrow, C, Di Giacomo, A M, Fisher, R, Sandhu, S, Kudchadkar, R, Ortiz Romero, P L, Svane, I M, Larkin, J, Puig, S, Hersey, P, Quaglino, P, Queirolo, P, Stroyakovskiy, D, Bastholt, L, Mohr, P, Hernberg, M, Chiarion-Sileni, V, Strother, M, Hauschild, A, Yamazaki, N, van Akkooi, A C, Lorigan, P, Krepler, C, Ibrahim, N, Marreaud, S, Kicinski, M, Suciu, S & Robert, C 2021, ' Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma ', European journal of cancer (Oxford, England : 1990), vol. 158, pp. 156-168 . https://doi.org/10.1016/j.ejca.2021.09.023Test
Eggermont, A M M, Meshcheryakov, A, Atkinson, V, Blank, C U, Mandala, M, Long, G V, Barrow, C, Di Giacomo, A M, Fisher, R, Sandhu, S, Kudchadkar, R, Romero, P L O, Svane, I M, Larkin, J, Puig, S, Hersey, P, Quaglino, P, Queirolo, P, Stroyakovskiy, D, Bastholt, L, Mohr, P, Hernberg, M, Chiarion-Sileni, V, Strother, M, Hauschild, A, Yamazaki, N, van Akkooi, A C, Lorigan, P, Krepler, C, Ibrahim, N, Marreaud, S, Kicinski, M, Suciu, S & Robert, C 2021, ' Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma ', European Journal of Cancer, vol. 158, pp. 156-168 . https://doi.org/10.1016/j.ejca.2021.09.023Test

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::206bf54251ce7ab0bcaf3dc33467c927Test
https://findresearcher.sdu.dk:8443/ws/files/194774299/PIIS0959804921006201.pdfTest

3

Immune checkpoint inhibitors in melanoma in the metastatic, neoadjuvant, and adjuvant setting

المؤلفون: Caroline Robert, Hugo Herrscher

المصدر: Current Opinion in Oncology. 32:106-113

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b215dfbe48092e82af5944056d7b08dTest
https://doi.org/10.1097/cco.0000000000000610Test

4

The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients

المؤلفون: Paolo A. Ascierto, Dirk Schadendorf, Selma Ugurel, Alexander M.M. Eggermont, Reinhardt Dummer, Elisabeth Livingstone, Lisa Zimmer, Anne Zaremba, Georgina V. Long, Caroline Robert

المساهمون: University of Zurich, Schadendorf, Dirk

وصف الملف: 906_Zaremba_A._et_al._The_concepts_of_rechallange_and_retreatment_with_immune_checkpoints_blockade_in_melanoma_patients_EJC_2021.pdf - application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0af59f477caa0569ca2410181854e889Test
https://www.zora.uzh.ch/id/eprint/206131Test/

5

Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study

المصدر: The Lancet Haematology. 6:e48-e57

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9bbd9674f94d50bfc313e086f1c3c714Test
https://doi.org/10.1016/s2352-3026Test(18)30175-3

6

Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma

المساهمون: HUS Comprehensive Cancer Center, Clinicum, Department of Oncology, Helsinki University Hospital Area

المصدر: Journal of Clinical Oncology
Robert, C, Long, G V, Brady, B, Dutriaux, C, Di Giacomo, A M, Mortier, L, Rutkowski, P, Hassel, J C, McNeil, C M, Kalinka, E A, Lebbé, C, Charles, J, Hernberg, M M, Savage, K J, Chiarion-Sileni, V, Mihalcioiu, C, Mauch, C, Arance, A, Cognetti, F, Ny, L, Schmidt, H, Schadendorf, D, Gogas, H, Zoco, J, Re, S, Ascierto, P A & Atkinson, V 2020, ' Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 38, no. 33, pp. 3937-3946 . https://doi.org/10.1200/JCO.20.00995Test

مصطلحات موضوعية: 0301 basic medicine, Oncology, Proto-Oncogene Proteins B-raf, Cancer Research, medicine.medical_specialty, 3122 Cancers, Medizin, Ipilimumab, Pembrolizumab, law.invention, 03 medical and health sciences, 0302 clinical medicine, Antineoplastic Agents, Immunological, Randomized controlled trial, law, Internal medicine, Original Reports, medicine, Humans, METASTATIC MELANOMA, Progression-free survival, PEMBROLIZUMAB, Survival rate, Melanoma, Antineoplastic Agents, Alkylating, COMPLETE RESPONSE, business.industry, IPILIMUMAB, Wild type, Progression-Free Survival, 3. Good health, Clinical trial, Dacarbazine, Survival Rate, 030104 developmental biology, Nivolumab, 030220 oncology & carcinogenesis, SURVIVAL, Metastatic melanoma, Complete response, Pembrolizumab, Ipilimumab, Survival, business, medicine.drug

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56e136a7f3cebfa513b285e44ed047f9Test
http://hdl.handle.net/10138/324446Test

7

Abstract CT233: Phase 2 clinical study to evaluate the efficacy and safety of intratumoral BO-112 in combination with pembrolizumab in patients with advanced melanoma that have progressive disease on anti-PD-1-based therapy

المصدر: Cancer Research. 81:CT233-CT233

مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, business.industry, Melanoma, Mucosal melanoma, Cancer, Pembrolizumab, medicine.disease, Internal medicine, medicine, Immunogenic cell death, Nivolumab, business, CD8, Progressive disease

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::9e9eb08af652def9008252a5262ad131Test
https://doi.org/10.1158/1538-7445.am2021-ct233Test

8

Inflammatory bowel disease and cancer response due to anti-CTLA-4: is it in the flora?

المؤلفون: Franck Carbonnel, Emilie Soularue, Christine Mateus, Caroline Robert, Patricia Lepage, Clélia Coutzac, Nathalie Chaput

المساهمون: Department of Gastroenterology, AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Université Paris Sud (Paris 11), Laboratoire d’Immunomonitoring en Oncologie (LIO), Analyse moléculaire, modélisation et imagerie de la maladie cancéreuse (AMMICa), Université Paris-Sud - Paris 11 (UP11)-Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris-Sud - Paris 11 (UP11)-Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), US23 Institut de recherche intégrée en cancérologie, Institut National de la Santé et de la Recherche Médicale (INSERM), Faculté de pharmacie, Université catholique du Graben, Service de dermatologie, Département de médecine oncologique [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), MICrobiologie de l'ALImentation au Service de la Santé (MICALIS), Institut National de la Recherche Agronomique (INRA)-AgroParisTech, Université Paris-Saclay

المصدر: Seminars in Immunopathology
Seminars in Immunopathology, Springer Verlag, 2017, 39 (3), pp.327-331. ⟨10.1007/s00281-016-0613-x⟩

مصطلحات موضوعية: 0301 basic medicine, [SDV]Life Sciences [q-bio], medicine.medical_treatment, Immunology, chemical and pharmacologic phenomena, Ipilimumab, Pembrolizumab, Gut flora, Inflammatory bowel disease, Immunomodulation, 03 medical and health sciences, 0302 clinical medicine, Cancer immunotherapy, Neoplasms, medicine, Humans, Immunology and Allergy, CTLA-4 Antigen, Molecular Targeted Therapy, Intestinal Mucosa, Enterocolitis, biology, business.industry, Antibodies, Monoclonal, Cancer, Colitis, Inflammatory Bowel Diseases, medicine.disease, biology.organism_classification, 3. Good health, Intestines, 030104 developmental biology, 030220 oncology & carcinogenesis, Immunotherapy, medicine.symptom, Nivolumab, business, medicine.drug